🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-526295-22-00
Authorised Phase I

A research trial in healthy participants to learn how a new formulation of JNJ‑77730614 is absorbed and processed by the body, and how well both the new formulation and the buccal delivery system (cup) are tolerated

2026-526295-22-00 · tracked via the Priya Life Science EU tracker
Sponsor
Janssen Cilag International
Sponsor type
Pharmaceutical company
Therapeutic area
Immune System Diseases
Decision date
23/09/2026
Enrollment target
40
Sites
Belgium

Condition studied

Healthy Participants

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-526295-22-00 on CTIS ↗ ← All trials in the EU